Cancer Second Opinion From China (2026): Pathology Review ~$115
A remote pathology review at Fudan University Shanghai Cancer Center is reported at about RMB 800 (~$115). A full second opinion — re-read plus treatment-plan review — is quoted per case. You don't fly anywhere for it.
This page is about buying certainty cheaply, in the one disease where certainty is everything.
What a China second opinion is — and isn't
Let's set the frame honestly. If you want a brand-name second opinion your US oncologist already reveres, Cleveland Clinic and MD Anderson sell that, at US prices. What a Chinese national cancer center offers is different and specific:
- 1. A pathology re-read at referral-center standard. Fudan University Shanghai Cancer Center (FUSCC) runs one of China's definitive referral pathology departments — the place other Chinese hospitals send hard slides. Its high-level expert pathology consultation service is publicized through official hospital channels, with remote pathology consultation reported at ~RMB 800 per case.
- 2. A treatment-plan review built on Asia-scale volume. Chinese flagship centers see case volumes per subspecialty that few Western hospitals match; a reviewer who sees your rare subtype weekly reads it differently than one who sees it yearly.
- 3. The feasibility answer nobody else sells: if your plan at home is stalled — on cost, waiting lists, or exhausted options — is treatment in China actually realistic for you? Which hospital, which protocol, what it costs, and whether options like CAR-T therapy are on the table for your case. That assessment is the genuinely unique product.
What it costs
| Item | Price | Source | Verified |
|---|---|---|---|
| Remote pathology consultation, FUSCC | ~RMB 800 (~$115) per case | FUSCC patient-services announcement (official account, republished) — reported figure; confirm current fee when booking | 2026-07-08 |
| On-site expert pathology consultation, FUSCC | Registration-based; immunohistochemistry billed on top if needed | Same source; itemized fees vary by case | 2026-07-08 |
| Full second-opinion package (pathology + subspecialty treatment-plan review + translated report) | Quoted case by case — ask us | — | — |
| US comparison (remote second opinions from major US centers) | We're verifying — ask us | — | — |
The pattern to notice: the pathology re-read — the highest-leverage step — costs about what a US hospital charges for parking. Immunohistochemistry panels, molecular tests, or a multidisciplinary (MDT) review add real money, but each is ordered only if your case needs it, and we put every add-on in the written quote first.
How the process runs
- 1. Collect: original pathology report, slides/blocks release from your hospital, imaging (DICOM) with reports, treatment timeline. You own these records; hospitals must release them to you.
- 2. Submit and re-read: slides couriered or re-cut; FUSCC pathology issues its report, typically with days-level turnaround once material is in hand (case-dependent).
- 3. Plan review: a subspecialty oncologist reviews the confirmed diagnosis against your treatment history.
- 4. Delivery, peer-to-peer: you receive the pathology report and consult summary professionally translated, formatted for your treating oncologist to read in five minutes — findings, concurrence or divergence, options, and (only if relevant) what a China treatment episode would look like and cost.
No step requires a flight. If the review does open a treatment path in China, you'll already have the feasibility math done.
Why trust these numbers
The anchor fee traces to the hospital's own patient-services announcement and is labeled as reported, with a confirm-at-booking caveat; package pricing is honestly "quoted per case" because it genuinely varies. We publish no revision-rate marketing statistics we can't source. Found a discrepancy? Tell us — we correct within 48 hours and log it.
Get a real quote
Send your case outline (diagnosis, stage, what's been done) and we'll map the exact second-opinion route, cost, and turnaround — in writing.
Get a quote — $9.90 — credited toward any later service.
This page is pricing and logistics information, not medical advice and not an inducement to change treatment. Any second opinion should be weighed with your treating oncologist.
Frequently asked questions
How much does a cancer second opinion from China cost?
The anchor: Fudan University Shanghai Cancer Center's remote pathology consultation is reported at about RMB 800 (~$115) per case via its official patient-services channel. A fuller package — pathology re-read plus a treatment-plan review by a subspecialty team — is quoted case by case; ask us.
Why would I get a second opinion from a Chinese cancer center?
Volume and feasibility. Centers like FUSCC read tens of thousands of referred pathology cases a year — its pathology department is a national referral standard — and a China-based review answers a question no US second opinion can: whether treatment in China (including CAR-T or trial access) is realistic for you, at what cost.
Does a pathology review actually change diagnoses?
Sometimes — that's why referral pathology exists as a discipline. Subtype and grading revisions can redirect treatment entirely, which is why major centers worldwide re-read outside slides before treating. We don't publish a revision-rate statistic because we haven't verified one.
How does the second opinion reach my own oncologist?
Peer-to-peer on paper: you receive a written pathology report and consult summary, professionally translated, structured so your treating oncologist can act on it — not a sales pitch for flying to China.
What do I need to send?
Pathology slides or blocks (or a locally re-cut set), the original pathology report, imaging with reports, and your treatment history. Nothing needs to travel that your current hospital can't release to you.